# 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

> **NCT04743661** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Pediatric Brain Tumor Consortium** · enrollment: 62 (estimated)

## Conditions studied

- Recurrent Medulloblastoma
- Recurrent Ependymoma

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** Temozolomide
- **DRUG:** Bevacizumab
- **DRUG:** Omburtamab I-131
- **DRUG:** Liothyronine
- **DRUG:** SSKI
- **DRUG:** Dexamethasone
- **DRUG:** Antipyretic
- **DRUG:** Antihistamine
- **DRUG:** anti-emetics

## Key facts

- **NCT ID:** NCT04743661
- **Lead sponsor:** Pediatric Brain Tumor Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-04-04
- **Primary completion:** 2026-03-31
- **Final completion:** 2027-09-30
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2026-02-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04743661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04743661, "131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04743661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*